<?xml version="1.0" encoding="UTF-8"?>
<p id="p0140">SARS-CoV-2 human infection may not only induce acute neurological complications but also subacute neurological disorders reminiscent of the supposed involvement of HCoV-OC43 in ADEM. More specifically, several cases of Guillain Barrè syndrome have been described in COVID-19 patients, with neurological symptoms emerging 5–10 days after the first respiratory symptoms (
 <xref rid="bb0150" ref-type="bibr">Camdessanche et al., 2020</xref>; 
 <xref rid="bb0590" ref-type="bibr">Padroni et al., 2020</xref>; 
 <xref rid="bb0680" ref-type="bibr">Sedaghat and Karimi, 2020</xref>; 
 <xref rid="bb0750" ref-type="bibr">Toscano et al., 2020</xref>; 
 <xref rid="bb0795" ref-type="bibr">Virani et al., 2020</xref>). Even though the majority of these patients were seriously ill, milder forms of the Guillain-Barrè syndrome are also observed in COVID-19 (
 <xref rid="bb0675" ref-type="bibr">Scheidl et al., 2020</xref>). Finally, the occurrence of Miller-Fisher syndrome, a variant of the Guillain-Barrè syndrome characterized by the tryad of ataxia, areflexia, and ophthalmoplegia, has also been reported in two COVID-19 patients (
 <xref rid="bb0295" ref-type="bibr">Gutierrez-Ortiz et al., 2020</xref>).
</p>
